134 related articles for article (PubMed ID: 8824349)
1. Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.
Wadler S; Haynes H; Schechner R; Rozenblit A; Wiernik PH
Invest New Drugs; 1996; 13(4):315-20. PubMed ID: 8824349
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Kaubisch A; Kaleya R; Haynes H; Rozenblit A; Wadler S
Cancer Chemother Pharmacol; 2004 Apr; 53(4):337-40. PubMed ID: 14704829
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
4. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296.
Wadler S; Brain C; Catalano P; Einzig AI; Cella D; Benson AB
Cancer J; 2002; 8(3):282-6. PubMed ID: 12074329
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Wadler S; Schwartz EL; Goldman M; Lyver A; Rader M; Zimmerman M; Itri L; Weinberg V; Wiernik PH
J Clin Oncol; 1989 Dec; 7(12):1769-75. PubMed ID: 2585018
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
Pazdur R; Ajani JJ; Abbruzzese JL; Belt RJ; Dakhil SR; Dubovsky D; Graham S; Pilat S; Winn R; Levin B
Cancer; 1992 Oct; 70(8):2073-6. PubMed ID: 1394037
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
10. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
12. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Wadler S; Fell S; Haynes H; Katz HJ; Rozenblit A; Kaleya R; Wiernik PH
Cancer; 1993 Mar; 71(5):1726-30. PubMed ID: 8448736
[TBL] [Abstract][Full Text] [Related]
13. [5-Fluorouracil and alpha-2a interferon in patients with hormone-refractory prostate cancer].
Shinohara N; Harabayashi T; Matsuda H; Nounaka O; Nonomura K; Koyanagi T; Nagomori S; Ohmuro H; Matsumara K; Demura T
Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1557-62. PubMed ID: 7474606
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
Pazdur R; Ajani JA; Winn R; Bearden J; Belt RJ; Pilat S; Hallinan R; Levin B
Cancer; 1992 Feb; 69(4):878-82. PubMed ID: 1735078
[TBL] [Abstract][Full Text] [Related]
15. Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Seymour MT; Johnson PW; Hall MR; Wrigley PF; Slevin ML
Br J Cancer; 1994 Oct; 70(4):719-23. PubMed ID: 7917927
[TBL] [Abstract][Full Text] [Related]
16. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
Cascinu S; Del Ferro E; Ligi M; Catalano G
Anticancer Drugs; 1996 Jul; 7(5):520-4. PubMed ID: 8862717
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study.
Palmeri S; Gebbia V; Rausa L
J Chemother; 1990 Oct; 2(5):327-30. PubMed ID: 2090772
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
